Trial Title:
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT ID:
NCT03175224
Condition:
Solid Tumors
Advanced Cancer
Renal Cancer
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
NSCLC
Lung Cancer
Brain Tumor
Glioblastoma Multiforme
EGFR Gene Mutation
MET Amplification
HGF
Thyroid Cancer
Pancreatic Cancer
Colon Cancer
MET Alteration
MET Fusion
Exon 14 Skipping
Conditions: Official terms:
Neoplasms
Lung Neoplasms
Glioblastoma
Kidney Neoplasms
Conditions: Keywords:
Advanced Solid Tumor
Relapsed Solid Tumor
Recurrent Solid Tumor
cMet exon 14 skipping
cMet fusion
GBM
HGF
EGFR positive
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
APL-101 Oral Capsules
Description:
Subjects will receive APL-101 capsules BID for oral administration.
Arm group label:
Basket of solid tumor with MET gene fusions except for primary CNS tumors
Arm group label:
Basket of tumor types MET amplification except for primary CNS tumors
Arm group label:
Basket of tumor types wild-type MET with over-expression of HGF and MET
Arm group label:
EGFR positive NSCLC MET amplification as an acquired resistance
Arm group label:
NSCLC Exon 14 MET Inhibitor Experienced
Arm group label:
NSCLC Exon 14 Skip Previously Treated
Arm group label:
NSCLC Exon 14 Skip Treatment Naive
Arm group label:
NSCLC MET amplification and EGFR wild-type
Arm group label:
Primary CNS tumors with MET alterations
Other name:
PLB-1001
Other name:
CBI-3103
Other name:
Bozitinib
Other name:
CBT-101
Other name:
Vebreltinib
Summary:
To assess:
- efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14
skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET
amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET
alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET
- efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of
NSCLC harboring EGFR activating mutations and developed acquired resistance with MET
amplification and disease progression after documented CR or PR with 1st line EGFR
inhibitors (EGFR-I)
Detailed description:
Phase 1 (lead-in stage of this study) enrollment has been completed.
In this Phase 2 study, efficacy, safety, and tolerability will be assessed in the
following cohorts:
- Cohort A-1: NSCLC EXON 14 skip mutation, previously untreated, MET inhibitor naive
(c-Met naïve, 1L)
- Cohort A-2: NSCLC EXON 14 skip mutation, previously treated with ≤ 3 prior lines in
unresectable or metastatic setting, MET inhibitor naive (c-Met naïve, 2/3L)
- Cohort B: NSCLC EXON 14 skip mutation, previously treated with ≤ 3 prior lines in
unresectable or metastatic setting, MET inhibitor experienced (c-Met experienced;
progressed on prior c-Met inhibitor)
- Cohort C: basket of tumor types (e.g., NSCLC, upper gastrointestinal [GI],
colorectal, hepatobiliary cancer) harboring MET amplification except for primary CNS
tumors, previously treated or previously untreated but refused standard treatment,
or if treatment was unavailable or unfeasible (≤ 3 prior lines in unresectable or
metastatic setting), MET inhibitor naïve
- Cohort C-1: NSCLC harboring MET amplification and wild-type epidermal growth factor
receptor (EGFR), previously treated; or untreated but refused standard treatment, or
if treatment was unavailable or unfeasible (≤ 3 prior lines in unresectable or
metastatic setting), MET inhibitor naïve
- Cohort C-2: EGFR positive NSCLC harboring MET amplification as an acquired
resistance, documented response with first-line EGFR-Inhibitor (PR or CR per RECIST
≥ 12 weeks), radiological documentation of disease progression per RECIST on
first-line EGFR inhibitor therapy, MET inhibitor naïve
- Cohort D: basket of tumor types except for primary CNS tumors harboring MET gene
fusions (e.g., NSCLC, upper GI, colorectal, hepatobiliary cancer), previously
treated; or previously untreated but refused standard treatment, or if treatment was
unavailable or unfeasible (≤ 3 prior lines in unresectable or metastatic setting),
MET inhibitor naïve
- Cohort E: primary CNS tumors with MET alterations (single or co-occurred MET fusion
including PTPRZ1-MET [ZM] fusion, MET Exon 14 skipping mutation, or MET
amplification), previously treated or previously untreated but refused standard
treatment, or if treatment was unavailable or unfeasible (≤ 3 prior lines), MET
inhibitor naïve
- Cohort F: basket of tumor types harboring wild-type MET with over-expression of HGF
and MET (e.g., NSCLC, upper GI, colorectal, hepatobiliary cancer or primary CNS
tumors), previously treated; or previously untreated but refused standard treatment,
or if treatment was unavailable or unfeasible (≤ 3 prior lines in unresectable or
metastatic setting), MET inhibitor naïve
Criteria for eligibility:
Criteria:
Major Inclusion Criteria:
1. Men and women 18 years of age or older.
2. 9 cohorts will be enrolled:
- Cohort A1 / Exon 14 NSCLC MET inhibitor naive in first line: Histologically or
cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies;
unresectable or metastatic disease (Stage 3b/4); treatment-naive subjects in
first line; not received any MET inhibitor and no known MET kinase inhibitor
resistance mutations
- Cohort A2 / Exon 14 NSCLC - MET inhibitor naïve: Histologically or
cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies;
unresectable or metastatic disease (Stage 3b/4); pretreated subjects refractory
to or intolerant of standard therapies with no more than three lines of prior
therapy in the unresectable or metastatic setting; not received any MET
inhibitor and no known MET kinase inhibitor resistance mutations
- Cohort B / Exon 14 NSCLC MET inhibitor experienced: ENROLLMENT COMPLETED
- Cohort C / MET amplification basket tumor types excluding primary CNS tumors:
Any solid tumor type regardless of histology excluding primary CNS tumors, with
MET amplification; unresectable or metastatic disease, refractory to or
intolerant of standard therapies, or refused standard therapies, or if therapy
was unavailable or unfeasible, with no more than 3 prior lines of therapy in
the unresectable or metastatic setting; not received any MET inhibitor and no
known MET kinase inhibitor resistance mutations
- Cohort C1 / MET amplification and wild-type EGFR NSCLC: NSCLC regardless of
histology, harboring MET amplification and wild-type EGFR; unresectable or
metastatic disease, previously untreated or treated with no more than 3 prior
lines of therapy in the unresectable or metastatic setting; not received any
MET inhibitor and no known MET kinase inhibitor resistance mutations
- Cohort C2 / EGFR positive NSCLC with acquired MET amplification (APL-101 Add-on
Therapy): Unresectable or metastatic NSCLC regardless of histology, harboring
EGFR activating mutations with acquired MET-Amplification as resistance
mechanism to the EGFR-I; developed resistance to first-line EGFR-inhibitor
therapy after an initial response (documented PR for at least 12 weeks);
radiological documentation of disease progression per RECIST on first-line EGFR
inhibitor therapy; currently on an EGFR-inhibitor therapy and agrees to receive
APL-101 as an add-on therapy during the study; no history of interstitial lung
disease (ILD)/pneumonitis, Grade ≥3 liver toxicity or QT prolongation with
EGFR-I therapy; not received any MET inhibitor and no known MET kinase
inhibitor resistance mutations
- Cohort D / MET fusion basket tumor types excluding primary CNS tumors: any
solid tumor type regardless of histology excluding primary CNS tumors;
unresectable or metastatic disease, refractory to or intolerant of standard
therapies, or refused standard therapies, or if therapy was unavailable or
unfeasible, with no more than 3 prior lines of therapy in the unresectable or
metastatic setting; not received any MET inhibitor and no known MET kinase
inhibitor resistance mutations
- Cohort E / Primary CNS tumors with MET alterations: subjects with primary CNS
tumors who meet inclusion criteria of MET dysregulations defined as single or
co-occurred MET fusion including PTPRZ1-MET (ZM) fusion, MET Exon 14 skipping
mutations, or MET amplification; refractory to or intolerant of standard
therapies, or refused standard therapies, or if therapy was unavailable or
unfeasible, with no more than 3 prior lines of therapy in the unresectable or
metastatic setting; not received any MET inhibitor and no known MET kinase
inhibitor resistance mutations; neurological symptoms controlled on a
stable/decreasing dose of steroids for at least 2 weeks before C1D1
- Cohort F / Basket tumor types harboring wild-type MET with over-expression of
HGF and MET: any solid tumor type regardless of histology harboring wild-type
MET with overexpression of HGF and MET; Unresectable or metastatic disease,
refractory to or intolerant of standard therapies, or refused standard
therapies, or if therapy was unavailable or unfeasible, with no more than 3
prior lines of therapy in the unresectable or metastatic setting; not received
any MET inhibitor and no known MET kinase inhibitor resistance mutations
3. Treated or untreated asymptomatic parenchymal CNS disease or leptomeningeal disease
is allowed.
4. Presence of ≥1 measurable lesion (scan done ≤28 days of C1D1) to serve as target
lesion according to relevant criteria
5. ECOG performance status of 0-1. For subjects with primary CNS tumors, KPS score ≥70.
6. Acceptable organ function
7. For all prior anticancer treatment, a duration of 30 days or 5 half-lives of the
agents used, whichever is shorter, must have elapsed, and any encountered toxicity
must have resolved to levels meeting all the other eligibility criteria prior to the
first dose of study treatment. Palliative radiotherapy to non-target lesions should
be completed within 2 weeks prior to APL-101 administration.
8. Adequate cardiac function
9. Women of child-bearing potential must have a negative serum or Beta-hCG at screening
or evidence of surgical sterility or evidence of post-menopausal status
10. No planned major surgery within 4 weeks of first dose of APL-101
11. Expected survival (life expectancy) ≥ 3 months from C1D1
12. Provision of sample; e.g. archival or a fresh tumor biopsy sample (if safe and
feasible) either from the primary or a metastatic site) or liquid biopsy sample (if
tumor tissue is insufficient or lacking, and approved by the sponsor) is required
for prospective central lab confirmation for study entry (subjects with previously
confirmed molecular status by the Sponsor designated central lab or FDA approved NGS
based MET testing may be exempted, subjected to Sponsor approval.
Major Exclusion Criteria:
1. Hypersensitivity to APL-101, excipients of the drug product, or other components of
the study treatment regimen.
2. Known actionable mutation/gene rearrangement of EGFR (except for NSCLC subjects in
Cohort C and C-2), ALK, ROS1, RET, NTRK, KRAS, and BRAF.
3. Use or intended use of any other investigational product, including herbal
medications, through Study Treatment Termination.
4. Active uncontrolled systemic bacterial, viral, or fungal infection or clinically
significant, active disease process, which in the opinion of the investigator makes
the risk: benefit unfavorable for the participation of the trial.
5. Life-threatening illness, significant organ system dysfunction or comorbid
conditions, or other reasons that, in the investigator's opinion, could compromise
the subject's safety or the integrity of the study outcomes, or interfere with the
absorption or metabolism of APL-101.
6. Unstable angina or myocardial infarction within 1 year prior to first dose of
APL-101, symptomatic or unstable arrhythmia requiring medical therapy, history of
congenital prolonged QT syndrome, prolonged QT interval corrected by Fridericia
formula (QTcF) at screening, or concurrent treatment with a medication that is a
known risk for prolonging the QT interval. Chronic controlled atrial fibrillation is
not excluded.
7. Historical seropositive results consistent with active infection for hepatitis C
virus (HCV) or hepatitis B virus (HBV) with high viral loads not actively managed
with antiviral therapy and human immunodeficiency virus (HIV) positive subjects who
are not clinically stable or controlled on their medication (asymptomatic subjects
with CD4+ T-cell (CD4+) counts ≥ 350 cells/μL and have not had an opportunistic
infection within the past 12 months prior to first dose of APL-101 would be eligible
for study entry. If history is unclear, relevant test(s) at Screening will be
required to confirm eligibility.
8. Known significant mental illness or other conditions such as active alcohol or other
substance abuse that, in the opinion of the investigator, predisposes the subject to
high risk of noncompliance with the protocol treatment or assessments.
9. Unable to swallow orally administered medication whole.
10. Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter drug absorption
11. Women who are breastfeeding
12. History of another malignancy within 3 years prior to C1D1. A subject with the
following malignancies is allowed if considered cured or unlikely to recur within 3
years:
1. Carcinoma of the skin without melanomatous features.
2. Curatively treated cervical carcinoma in situ.
3. Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma
in situ (T1s), thyroid papillary cancer with prior treatment, prostate cancer
which has been surgically or medically treated and not likely to recur within 3
years.
13. Subjects who are unable or unwilling to discontinue excluded medications (drugs with
known QTc risk and known strong cytochrome P450 [CYP]3A4 inducer and/or strong
inhibitors) for at least 5 half-lives prior to first dose of study drug. Subjects
may qualify if such medication(s) can be safely replaced with alternate medications
with less risk of drug-drug interaction.
14. Subjects with active COVID-19 infection.
15. Symptomatic and/or neurologically unstable CNS metastases, or who require an
increase in steroid dose to control CNS disease. Subjects who have been receiving a
stable steroid dose for at least 2 weeks prior to C1D1 may be allowed.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Loma Linda University Medical Center
Address:
City:
Loma Linda
Zip:
92354
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
University of Southern California / Norris Comprehensive Cancer Center
Address:
City:
Los Angeles
Zip:
90033
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute
Address:
City:
Los Angeles
Zip:
90048
Country:
United States
Status:
Recruiting
Facility:
Name:
Kaiser Permanente - CA
Address:
City:
Riverside
Zip:
92505
Country:
United States
Status:
Recruiting
Facility:
Name:
UCSF - Helen Diller Family Comprehensive Cancer Center
Address:
City:
San Francisco
Zip:
94158
Country:
United States
Status:
Not yet recruiting
Facility:
Name:
Providence Medical Foundation
Address:
City:
Santa Monica
Zip:
90404
Country:
United States
Status:
Recruiting
Facility:
Name:
Providence St. Joseph Health
Address:
City:
Santa Rosa
Zip:
95403
Country:
United States
Status:
Recruiting
Facility:
Name:
Kaiser Permanente - Vallejo
Address:
City:
Vallejo
Zip:
94589
Country:
United States
Status:
Recruiting
Facility:
Name:
Christiana Hospital
Address:
City:
Newark
Zip:
19713
Country:
United States
Status:
Recruiting
Facility:
Name:
Florida Cancer Specialists - South
Address:
City:
Fort Myers
Zip:
33908
Country:
United States
Status:
Recruiting
Facility:
Name:
Miami Cancer Institute
Address:
City:
Miami
Zip:
33176
Country:
United States
Status:
Recruiting
Facility:
Name:
Florida Cancer Specialists - North
Address:
City:
Saint Petersburg
Zip:
33705
Country:
United States
Status:
Recruiting
Facility:
Name:
Florida Cancer Specialists
Address:
City:
Tallahassee
Zip:
32308
Country:
United States
Status:
Recruiting
Facility:
Name:
Moffitt
Address:
City:
Tampa
Zip:
33612
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
Florida Cancer Specialists
Address:
City:
West Palm Beach
Zip:
33401
Country:
United States
Status:
Recruiting
Facility:
Name:
Maryland Oncology Hematology
Address:
City:
Silver Spring
Zip:
20904
Country:
United States
Status:
Recruiting
Facility:
Name:
Beth Israel Deaconess Medical Center
Address:
City:
Boston
Zip:
02215
Country:
United States
Status:
Recruiting
Facility:
Name:
Dana Farber Cancer Institute
Address:
City:
Boston
Zip:
02215
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
Mayo Clinic
Address:
City:
Rochester
Zip:
55905
Country:
United States
Status:
Active, not recruiting
Facility:
Name:
HealthPartners Cancer Research Center
Address:
City:
Saint Louis Park
Zip:
55416
Country:
United States
Status:
Recruiting
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Facility:
Name:
University of North Carolina
Address:
City:
Chapel Hill
Zip:
27599
Country:
United States
Status:
Recruiting
Facility:
Name:
Wake Forest University Health Sciences
Address:
City:
Winston-Salem
Zip:
27157
Country:
United States
Status:
Recruiting
Facility:
Name:
The Ohio State University (OSU)
Address:
City:
Columbus
Zip:
43210
Country:
United States
Status:
Recruiting
Facility:
Name:
Ohio Health Research Institute
Address:
City:
Columbus
Zip:
43214
Country:
United States
Status:
Recruiting
Facility:
Name:
Penn State Milton S. Hershey Medical Center
Address:
City:
Hershey
Zip:
17033
Country:
United States
Status:
Recruiting
Facility:
Name:
St. Francis Cancer Center
Address:
City:
Greenville
Zip:
29607
Country:
United States
Status:
Recruiting
Facility:
Name:
Sarah Cannon and HCA Research Institute
Address:
City:
Nashville
Zip:
37203
Country:
United States
Status:
Recruiting
Facility:
Name:
The Don & Sybil Harrington Cancer Center
Address:
City:
Amarillo
Zip:
79106
Country:
United States
Status:
Recruiting
Facility:
Name:
West Virginia University Cancer Institute
Address:
City:
Morgantown
Zip:
26506
Country:
United States
Status:
Recruiting
Contact:
Last name:
BSN
Facility:
Name:
University of Wisconsin
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Facility:
Name:
Flinders Medical Centre
Address:
City:
Bedford Park
Country:
Australia
Status:
Recruiting
Facility:
Name:
Border Medical Oncology
Address:
City:
Albury
Country:
Australia
Status:
Recruiting
Facility:
Name:
Peninsula and Southeast Oncology
Address:
City:
Frankston
Country:
Australia
Status:
Recruiting
Facility:
Name:
St Vincents Hospital Melbourne
Address:
City:
Melbourne
Country:
Australia
Status:
Recruiting
Facility:
Name:
Sir Charles Gairdner Hospital
Address:
City:
Nedlands
Country:
Australia
Status:
Recruiting
Facility:
Name:
Calvary Central Districts Hospita
Address:
City:
North Adelaide
Country:
Australia
Status:
Active, not recruiting
Facility:
Name:
Lady Davis Institute for Medical Research Jewish General Hospital
Address:
City:
Montreal
Country:
Canada
Status:
Recruiting
Facility:
Name:
Cross Cancer Institute
Address:
City:
Edmonton
Country:
Canada
Status:
Recruiting
Facility:
Name:
McGill University Health Center - Research Institute
Address:
City:
Montréal
Country:
Canada
Status:
Recruiting
Facility:
Name:
Princess Margaret Hospital
Address:
City:
Toronto
Country:
Canada
Status:
Recruiting
Facility:
Name:
Cancer Care Manitoba
Address:
City:
Winnipeg
Country:
Canada
Status:
Recruiting
Facility:
Name:
Tampere University Hospital
Address:
City:
Tampere
Country:
Finland
Status:
Recruiting
Facility:
Name:
CHRU de Brest - Hôpital Morvan
Address:
City:
Brest
Country:
France
Status:
Recruiting
Facility:
Name:
CHRU de Lille
Address:
City:
Lille
Country:
France
Status:
Recruiting
Facility:
Name:
Centre Leon Berard
Address:
City:
Lyon
Country:
France
Status:
Recruiting
Facility:
Name:
Centre d'Essais Precoces en Cancerologie de Marseille
Address:
City:
Marseille
Country:
France
Status:
Recruiting
Facility:
Name:
Hopital Bichat - Claude Bernard - AP-HP
Address:
City:
Paris
Country:
France
Status:
Recruiting
Facility:
Name:
CHU Rennes - Hopital Pontchaillou
Address:
City:
Rennes
Country:
France
Status:
Recruiting
Facility:
Name:
Gustave Roussy
Address:
City:
Villejuif
Country:
France
Status:
Recruiting
Facility:
Name:
Orszagos Koranyi Pulmonologiai Intezet
Address:
City:
Budapest
Country:
Hungary
Status:
Recruiting
Facility:
Name:
Szent Borbala Korhaz
Address:
City:
Tatabanya
Country:
Hungary
Status:
Recruiting
Facility:
Name:
Torokbalinti Tudogyogyintezet
Address:
City:
Torokbalint
Country:
Hungary
Status:
Recruiting
Facility:
Name:
Azienda Ospedaliero-Universitaria delle Marche
Address:
City:
Ancona
Zip:
60126
Country:
Italy
Status:
Recruiting
Facility:
Name:
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
Address:
City:
Bologna
Country:
Italy
Status:
Recruiting
Facility:
Name:
Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico
Address:
City:
Catania
Country:
Italy
Status:
Recruiting
Facility:
Name:
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Address:
City:
Meldola
Country:
Italy
Status:
Recruiting
Facility:
Name:
Istituto Europeo di Oncologia
Address:
City:
Milano
Country:
Italy
Status:
Recruiting
Facility:
Name:
IRCCS Ospedale San Raffaele
Address:
City:
Milan
Country:
Italy
Status:
Recruiting
Facility:
Name:
Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera
Address:
City:
Padova
Country:
Italy
Status:
Recruiting
Facility:
Name:
AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette
Address:
City:
Torino
Country:
Italy
Status:
Recruiting
Facility:
Name:
PanOncology Trials, LLC
Address:
City:
Rio Piedras
Country:
Puerto Rico
Status:
Recruiting
Facility:
Name:
Arkhangelsk Clinical Oncological Dispensary
Address:
City:
Arkhangelsk
Country:
Russian Federation
Status:
Active, not recruiting
Facility:
Name:
JSC Group of companies Medsi
Address:
City:
Otradnoye
Country:
Russian Federation
Status:
Active, not recruiting
Facility:
Name:
Private Medical Institution Euromedservice
Address:
City:
Saint Petersburg
Country:
Russian Federation
Status:
Active, not recruiting
Facility:
Name:
Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology)
Address:
City:
Saint Petersburg
Country:
Russian Federation
Status:
Active, not recruiting
Facility:
Name:
Ogarev Mordovia State University
Address:
City:
Saransk
Country:
Russian Federation
Status:
Active, not recruiting
Facility:
Name:
JSC Current Medical Technologies
Address:
City:
St. Petersburg
Country:
Russian Federation
Status:
Active, not recruiting
Facility:
Name:
Volgograd Regional Clinical Oncology Dispensary
Address:
City:
Volgograd
Country:
Russian Federation
Status:
Active, not recruiting
Facility:
Name:
National Cancer Centre Singapore
Address:
City:
Singapore
Country:
Singapore
Status:
Recruiting
Facility:
Name:
Oncocare Cancer Centre
Address:
City:
Singapore
Country:
Singapore
Status:
Recruiting
Facility:
Name:
Tan Tock Seng Hospital
Address:
City:
Singapore
Country:
Singapore
Status:
Recruiting
Facility:
Name:
Hospital Germans Trias i Pujol
Address:
City:
Badalona
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Clinic Barcelona
Address:
City:
Barcelona
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital del Mar
Address:
City:
Barcelona
Country:
Spain
Status:
Recruiting
Facility:
Name:
Institut Catala d'Oncologia - L'Hospitalet
Address:
City:
Barcelona
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital General Universitario Gregorio Maranon
Address:
City:
Madrid
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Universitario 12 de Octubre
Address:
City:
Madrid
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Universitario Puerta de Hierro Majadahonda
Address:
City:
Madrid
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Universitario Ramon y Cajal
Address:
City:
Madrid
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Universitario Central de Asturias
Address:
City:
Oviedo
Country:
Spain
Status:
Recruiting
Facility:
Name:
Hospital Universitario Virgen del Rocio
Address:
City:
Sevilla
Country:
Spain
Status:
Recruiting
Facility:
Name:
Instituto Valenciano de Oncologia
Address:
City:
Valencia
Country:
Spain
Status:
Recruiting
Facility:
Name:
Taichung Veterans General Hospital
Address:
City:
Taichung
Country:
Taiwan
Status:
Recruiting
Facility:
Name:
Chi-Mei Hospital - Liouying Branch
Address:
City:
Tainan
Country:
Taiwan
Status:
Recruiting
Facility:
Name:
National Taiwan University Hospital
Address:
City:
Taipei City
Country:
Taiwan
Status:
Recruiting
Facility:
Name:
Linkou Chang Gung Memorial Hospital (CGMHLK)
Address:
City:
Taoyuan City
Country:
Taiwan
Status:
Recruiting
Facility:
Name:
Imperial College Healthcare NHS Trust
Address:
City:
London
Country:
United Kingdom
Status:
Active, not recruiting
Facility:
Name:
University College London Hospital
Address:
City:
London
Country:
United Kingdom
Status:
Recruiting
Facility:
Name:
The Christie NHS Foundation Trust
Address:
City:
Manchester
Country:
United Kingdom
Status:
Recruiting
Facility:
Name:
Royal Marsden Hospital - Surrey
Address:
City:
Surrey Quays
Country:
United Kingdom
Status:
Recruiting
Start date:
September 27, 2017
Completion date:
November 30, 2026
Lead sponsor:
Agency:
Apollomics Inc.
Agency class:
Industry
Source:
Apollomics Inc.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT03175224
https://www.apollomicsinc.com
